Canadian psychedelic biotechnology company BetterLife Pharma has raised USD 1.1 million via a private placement. The offering consists of units priced at USD 0.15, each comprising one common share and a warrant to purchase one common share at an exercise price of USD 0.20 for up to two years from the date of the closing of the private placement, which is subject to regulatory and other approvals.
The new funds will be allocated toward advancing its lead compound, BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (LSD), and for general working capital purposes.
Analyst QuickTake: In April 2024 , the company raised USD 74,000 by issuing convertible debentures. This continuous raising of funds underscores BetterLife Pharma's commitment to advancing BETR-001, especially following the FDA's grant of breakthrough therapy designation to MindMed, a psychedelic biotech company, for its LSD-based MM120 program to treat generalized anxiety disorder.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.